4//SEC Filing
Alland Leila 4
Accession 0001209191-21-050670
CIK 0001699382other
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 6:14 PM ET
Size
12.7 KB
Accession
0001209191-21-050670
Insider Transaction Report
Form 4
Alland Leila
Chief Medical Officer
Transactions
- Sale
Common Stock
2021-08-09$35.06/sh−2,198$77,070→ 1,802 total - Exercise/Conversion
Common Stock
2021-08-09$3.90/sh+4,000$15,600→ 4,000 total - Sale
Common Stock
2021-08-09$36.69/sh−224$8,219→ 0 total - Sale
Common Stock
2021-08-09$32.66/sh−2,049$66,914→ 224 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-08-09−4,000→ 357,850 totalExercise: $3.90Exp: 2030-02-04→ Common Stock (4,000 underlying)
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.575 to $35.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.605 to $36.50, inclusive.
- [F4]One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.
Documents
Issuer
PMV Pharmaceuticals, Inc.
CIK 0001699382
Entity typeother
Related Parties
1- filerCIK 0001825216
Filing Metadata
- Form type
- 4
- Filed
- Aug 9, 8:00 PM ET
- Accepted
- Aug 10, 6:14 PM ET
- Size
- 12.7 KB